Clave Capital
VC Fund
Jardim Paulista, Brazil
Clave Capital is an independent asset management company that specializes in investment strategy.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Clave Capital invests in
Stages Clave Capital invests in
Countries Clave Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $653k–$7.3M
- Venture - Series Unknown
- $6.1M–$31M
Investment Focus
Industry
- Biotechnology 4 (44%)
- Health Diagnostics 3 (33%)
- Health Care 2 (22%)
- Pharmaceutical 2 (22%)
- Mobile 1 (11%)
Stage
- Seed 3 (33%)
- Venture - Series Unknown 2 (22%)
- Series A 1 (11%)
Country
- Spain 5 (56%)
- Brazil 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel Nader
Partner and Head of Real Estate
|
Partner and Head of Real Estate | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively targetthe cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. | $14.1M / Series A / Oct 06, 2025 | ||
| Turbi is a digital shared mobility company that makes car rental experience practical, cheaper and unique | $30.8M / Venture - Series Unknown / Jan 11, 2024 | ||
| MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $4.2M / Seed / Nov 27, 2023 | ||
| Nanological is a public research organization, that focuses on pathogen identification devices. Nanological is a team of biosensing experts including physicists, biologists, data scientists, finance and business development experts, and clinical validation specialists. | $653.3K / Seed / Nov 22, 2023 | ||
| ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer. | $6.1M / Venture - Series Unknown / Jul 19, 2023 | ||
| OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez. | $7.3M / Seed / Jun 22, 2023 | ||
| MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $1.1M / Seed / Jun 08, 2023 | ||
| See all 9 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Clave Capital invest in?
Clave Capital invests primarily in Biotechnology, Health Diagnostics and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 9 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Clave Capital's check size?
Clave Capital typically joins rounds of $653k–$7.3M at Seed and $6.1M–$31M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Clave Capital participates in.
How do I contact Clave Capital?
Public channels for Clave Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Clave Capital?
The team at Clave Capital includes Daniel Nader (Partner and Head of Real Estate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
